MedPath

Rabeprazole

Generic Name
Rabeprazole
Brand Names
Aciphex, Pariet
Drug Type
Small Molecule
Chemical Formula
C18H21N3O3S
CAS Number
117976-89-3
Unique Ingredient Identifier
32828355LL
Background

Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.

Indication

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.

Associated Conditions
Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
Clinical Trials
Related News

Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat

Phase 1
Completed
Conditions
Drug Interaction Potentiation
Pharmacokinetics
Interventions
First Posted Date
2018-12-28
Last Posted Date
2019-03-22
Lead Sponsor
Akebia Therapeutics
Target Recruit Count
20
Registration Number
NCT03789032
Locations
🇨🇦

inVentiv Health Clinique Inc., Québec City, Quebec, Canada

Evaluation of Rebamipide and Rabeprazole Effect Associated or Not to Prevent Naproxen-induced Gastric Lesions

First Posted Date
2018-09-05
Last Posted Date
2018-09-05
Lead Sponsor
Galeno Desenvolvimento de Pesquisas Clínicas
Target Recruit Count
32
Registration Number
NCT03658473
Locations
🇧🇷

Galeno Desenvolvimento de Pesquisas Clinicas Ltda., Campinas, SP, Brazil

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

Phase 1
Completed
Conditions
Drug-drug Interaction
Autoimmune Diseases
Fibrotic Disease
Interventions
First Posted Date
2018-05-21
Last Posted Date
2022-05-25
Lead Sponsor
Kadmon Corporation, LLC
Target Recruit Count
73
Registration Number
NCT03530995
Locations
🇬🇧

Quotient Sciences Ltd, Ruddington, Nottingham, United Kingdom

Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: BOS172767 tablets
Drug: BOS172767 micronized capsules
Drug: BOS172767 liquid capsules
Drug: BOS172767 immediate release capsules
Drug: BOS172767 matching placebo capsules
Drug: BOS172767 matching placebo tablets
First Posted Date
2018-03-13
Last Posted Date
2020-11-18
Lead Sponsor
Boston Pharmaceuticals
Target Recruit Count
28
Registration Number
NCT03464058
Locations
🇬🇧

Quotient Sciences, Nottingham, United Kingdom

Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases

Not Applicable
Completed
Conditions
Peptic Ulcer Disease
Interventions
Other: Placebo
Other: Hou Gu Mi Xi
First Posted Date
2017-10-25
Last Posted Date
2024-07-03
Lead Sponsor
Jiangxi University of Traditional Chinese Medicine
Target Recruit Count
360
Registration Number
NCT03320538
Locations
🇨🇳

Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, China

A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2017-09-25
Last Posted Date
2019-09-11
Lead Sponsor
Genentech, Inc.
Target Recruit Count
63
Registration Number
NCT03290703
Locations
🇬🇧

Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom

Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants

Phase 1
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
First Posted Date
2017-08-02
Last Posted Date
2024-03-01
Lead Sponsor
Genentech, Inc.
Target Recruit Count
18
Registration Number
NCT03237741
Locations
🇬🇧

Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom

Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
First Posted Date
2017-07-18
Last Posted Date
2017-10-10
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT03220191
Locations
🇺🇸

Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication

Phase 4
Conditions
Helicobacter Pylori Infection
Interventions
First Posted Date
2017-04-28
Last Posted Date
2017-04-28
Lead Sponsor
Indonesia University
Target Recruit Count
73
Registration Number
NCT03134378
Locations
🇮🇩

Cipto Mangunkusumo Hospital, Jakarta Pusat, DKI Jakarta, Indonesia

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Other: High Fat, High Calorie Meal
First Posted Date
2017-04-26
Last Posted Date
2017-08-01
Lead Sponsor
Pfizer
Target Recruit Count
24
Registration Number
NCT03130556
Locations
🇺🇸

Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy